Ken Griffin Insulet Corp Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$163.6 - $209.11 $8.11 Million - $10.4 Million	-49,600 Reduced 33.13%	100,100 $17.2 Million
Q4 2023 Feb 14, 2024	SELL	$127.77 - $221.42 $127,770 - $221,420	-1,000 Reduced 0.66%	149,700 $32.5 Million
Q3 2023 Nov 14, 2023	BUY	$154.67 - $290.89 $16.3 Million - $30.7 Million	105,600 Added 234.15%	150,700 $24 Million
Q2 2023 Aug 14, 2023	SELL	$272.48 - $330.23 $29.1 Million - $35.3 Million	-106,900 Reduced 70.33%	45,100 $13 Million
Q1 2023 May 15, 2023	BUY	$276.36 - $326.03 $29.5 Million - $34.8 Million	106,600 Added 234.8%	152,000 $48.5 Million

Q4 2022 Feb 14, 2023	BUY	$212.22 - $313.46 $3.29 Million - $4.86 Million	15,500 Added 51.84%	45,400 $13.4 Million
Q3 2022 Nov 14, 2022	SELL	$224.6 - $281.45 $7.39 Million - $9.26 Million	-32,900 Reduced 52.39%	29,900 $6.86 Million

614

62.9M

339K

916K

Ticker PODD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 69,403,600
Market Cap $14.3B
Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sel...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.